The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats

Journal of Clinical Investigation

Volumn 118, Issue 3, 2008, Pages 868-878

  Morimoto, Tatsuya ^a   Sunagawa, Yoichi ^a   Kawamura, Teruhisa ^a   Takaya, Tomohide ^a,b   Wada, Hiromichi ^a   Nagasawa, Atsushi ^b   Komeda, Masashi ^b   Fujita, Masatoshi ^b   Shimatsu, Akira ^a   Kita, Toru ^b   Hasegawa, Koji ^a  

^a NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CURCUMIN; HISTONE ACETYLTRANSFERASE PCAF;

ACETYLATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DIETARY INTAKE; DNA BINDING; DRUG INHIBITION; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CELL; HYPERTENSION; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT;

ACETYLATION; ANIMALS; CARDIOMEGALY; CURCUMIN; DNA; ENZYME INHIBITORS; GATA4 TRANSCRIPTION FACTOR; HEART FAILURE; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; P300-CBP TRANSCRIPTION FACTORS; RATS; SYSTOLE; VENTRICULAR FUNCTION, LEFT;

EID: 40549135974     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI33160     Document Type: Article

References (38)

1. Ho, K.K., Levy, D., Kannel, W.B., and Pinsky, J.L. 1993. The epidemiology of heart failure: the Framingham study. J. Am. Coll. Cardiol. 22:6-13.
2. Dominguez, L.J., Parrinello, G., Amato, P., and Licata, G. 1999. Trends of congestive heart failure epidemiology: contrast with clinical trial results. Cardiologia. 44:801-808.
3. Dorn, G.W., II, Robbins, J., and Sugden, P.H. 2003. Phenotyping hypertrophy: eschew obfuscation. Circ. Res. 92:1171-1175.
4. Frey, N., and Olson, E.N. 2003. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65:45-79.
5. Chien, K.R. 1999. Stress pathways and heart failure. Cell. 98:555-558.
6. Lohse, M.J., Engelhardt, S., and Eschenhagen, T. 2003. What is the role of β-adrenergic signaling in heart failure? Circ. Res. 93:896-906.
7. Molkentin, J.D., and Dorn, I.G., II. 2001. Cytoplasmic signaling pathways that regulate cardiac hypertrophy. Annu. Rev. Physiol. 63:391-426.
8. Chien, K.R., et al. 1993. Transcriptional regulation during cardiac growth and development. Annu. Rev. Physiol. 55:77-95.
9. Kolodziejczyk, S.M., et al. 1999. MEF2 is upregulated during cardiac hypertrophy and is required for normal post-natal growth of the myocardium. Curr. Biol. 9:1203-1206.
10. Herzig, T.C., et al. 1997. Angiotensin II type Ia receptor gene expression in the heart: AP-1 and GATA-4 participate in the response to pressure overload. Proc. Natl. Acad. Sci. U. S. A. 94:7543-7548.
11. Hasegawa, K., Lee, S.J., Jobe, S.M., Markham, B.E., and Kitsis, R.N. 1997. cis-Acting sequences that mediate induction of beta-myosin heavy chain gene expression during left ventricular hypertrophy due to aortic constriction. Circulation. 96:3943-3953.
12. Backs, J., and Olson, E.N. 2006. Control of cardiac growth by histone acetylation/deacetylation. Circ. Res. 98:15-24.
13. McKinsey, T.A., and Olson, E.N. 2004. Cardiac histone acetylation-therapeutic opportunities abound. Trends Genet. 20:206-213.
14. Dai, Y.S., and Markham, B.E. 2001. p300 Functions as a coactivator of transcription factor GATA-4. J. Biol. Chem. 276:37178-37185.
15. Kakita, T., et al. 1999. p300 protein as a coactivator of GATA-5 in the transcription of cardiac-restricted atrial natriuretic factor gene. J. Biol. Chem. 274:34096-34102.
16. Yanazume, T., et al. 2003. Cardiac p300 is involved in myocyte growth with decompensated heart failure. Mol. Cell. Biol. 23:3593-3606.
17. Miyamoto, S., et al. 2006. Histone acetyltransferase activity of p300 is required for the promotion of left ventricular remodeling after myocardial infarction in adult mice in vivo. Circulation. 113:679-690.
18. Lau, O.D., et al. 2000. HATs off: selective synthetic inhibitors of the histone acetyltransferases p300 and PCAF. Mol. Cell. 5:589-595.
19. Cebrat, M., Kim, C.M., Thompson, P.R., Daugherty, M., and Cole, P.A. 2003. Synthesis and analysis of potential prodrugs of coenzyme A analogues for the inhibition of the histone acetyltransferase p300. Bioorg. Med. Chem. 11:3307-3313.
20. Balasubramanyam, K., Swaminathan, V., Ranganathan, A., and Kundu, T.K. 2003. Small molecule modulators of histone acetyltransferase p300. J. Biol. Chem. 278:19134-19140.
21. Balasubramanyam, K., et al. 2004. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J. Biol. Chem. 279:33716-33726.
22. Balasubramanyam, K., et al. 2004. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J. Biol. Chem. 279:51163-51171.
23. Yao, T.P., et al. 1998. Gene dosage-dependent embryonic development and proliferation defects in mice lacking the transcriptional integrator p300. Cell. 93:361-372.
24. Shikama, N., et al. 2003. Essential function of p300 acetyltransferase activity in heart, lung and small intestine formation. EMBO J. 22:5175-5185.
25. Kawamura, T., et al. 2004. Expression of p300 protects cardiac myocytes from apoptosis in vivo. Biochem. Biophys. Res. Commun. 315:733-738.
26. Thompson, P.R., et al. 2004. Regulation of the p300 HAT domain via a novel activation loop. Nat. Struct. Mol. Biol. 11:308-315.
27. Black, J.C., Choi, J.E., Lombardo, S.R., and Carey, M. 2006. A mechanism for coordinating chromatin modification and preinitiation complex assembly. Mol. Cell. 23:809-818.
28. Gardner, D.G. 2003. Natriuretic peptides: markers or modulators of cardiac hypertrophy? Trends Endocrinol. Metab. 14:411-416.
29. Sano, M., et al. 2007. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature. 446:444-448.
30. Aggarwal, B.B., and Shishodia, S. 2006. Molecular targets of dietary agents for prevention and therapy of cancer. Biochem. Pharmacol. 71:1397-1421.
31. Purcell, N.H., et al. 2001. Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc. Natl. Acad. Sci. U. S. A. 98:6668-6673.
32. Alter, P., Rupp, H., and Maisch, B. 2006. Activated nuclear transcription factor kappaB in patients with myocarditis and dilated cardiomyopathy - relation to inflammation and cardiac function. Biochem. Biophys. Res. Commun. 339:180-187.
33. Manikandan, P., et al. 2004. Curcumin modulates free radical quenching in myocardial ischemia in rats. Int. J. Biochem. Cell Biol. 36:1967-1980.
34. Sharma, R.A., et al. 2001. Pharmacodynamic and pharmacokinetic study of oral Curcuma extract in patients with colorectal cancer. Clin. Cancer Res. 7:1894-1900.
35. Hirai, M., et al. 2004. FOG-2 competes with GATA-4 for transcriptional coactivator p300 and represses hypertrophic responses in cardiac myocytes. J. Biol. Chem. 279:37640-37650.
36. Kawamura, T., et al. 2005. Acetylation of GATA-4 is involved in the differentiation of embryonic stem cells into cardiac myocytes. J. Biol. Chem. 280:19682-19688.
37. Morimoto, T., et al. 2000. Phosphorylation of GATA-4 is involved in α1-adrenergic agonist-responsive transcription of the Endothelin-1 gene in cardiac myocytes. J. Biol. Chem. 275:13721-13726.
38. Tambara, K., et al. 2003. Transplanted skeletal myoblasts can fully replace the infarcted myocardium when they survive in the host in large numbers. Circulation. 108(Suppl. 1):II259-II263.